BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26825695)

  • 1. Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?
    Finn LE; Foran JM
    Curr Opin Hematol; 2016 Mar; 23(2):95-101. PubMed ID: 26825695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia.
    Stone RM; O'Donnell MR; Sekeres MA
    Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should autotransplantation in acute myeloid leukemia in first complete remission be revisited?
    Zuckerman T; Beyar-Katz O; Rowe JM
    Curr Opin Hematol; 2016 Mar; 23(2):88-94. PubMed ID: 26825697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
    Buccisano F; Walter RB
    Curr Opin Hematol; 2017 Mar; 24(2):132-138. PubMed ID: 27930388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.
    Sengsayadeth S; Savani BN; Blaise D; Malard F; Nagler A; Mohty M
    Haematologica; 2015 Jul; 100(7):859-69. PubMed ID: 26130513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
    Song KW; Lipton J
    Bone Marrow Transplant; 2005 Aug; 36(3):183-91. PubMed ID: 15937497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
    Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
    Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
    Lim SJ; Lim MJ; Raptis A; Hou JZ; Farah R; Marks SM; Im A; Dorritie K; Sehgal A; Agha M; Felgar R; Lim SH
    Am J Hematol; 2015 Aug; 90(8):715-8. PubMed ID: 26010177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.
    Michaelis LC; Erba HP
    Curr Opin Hematol; 2015 Mar; 22(2):108-15. PubMed ID: 25603478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.
    Stelljes M; Krug U; Beelen DW; Braess J; Sauerland MC; Heinecke A; Ligges S; Sauer T; Tschanter P; Thoennissen GB; Berning B; Kolb HJ; Reichle A; Holler E; Schwerdtfeger R; Arnold R; Scheid C; Müller-Tidow C; Woermann BJ; Hiddemann W; Berdel WE; Büchner T
    J Clin Oncol; 2014 Feb; 32(4):288-96. PubMed ID: 24366930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
    Michelis FV; Messner HA; Atenafu EG; Kim DD; Kuruvilla J; Lipton JH; Uhm J; Loach D; Gupta V
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):474-9. PubMed ID: 24345422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic stem cell transplantation in the management of acute myeloid leukemia].
    Schmid C; Kolb HJ
    Med Klin (Munich); 2007 Apr; 102(4):317-23. PubMed ID: 17426935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
    Gyurkocza B; Lazarus HM; Giralt S
    Bone Marrow Transplant; 2017 Aug; 52(8):1083-1090. PubMed ID: 28244979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach to patients with primary refractory acute myeloid leukemia.
    Orlowski RJ; Mangan JK; Luger SM
    Curr Opin Hematol; 2015 Mar; 22(2):97-107. PubMed ID: 25575037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
    Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
    Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
    Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.